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ABSTRACT 
The field of epigenetic has witnessed a recent breakthrough in our information and stands at 
the forefront of biomedical research. Epigenetic alterations may result in changes in chromatin 
structure leading to a deregulation of gene expression associated with various diseases. Cancer has 
been deliberated to be brought about by a wide variety of genetic and genomic alterations. However, 
cancer development is not limited to the genetic changes, but may also include epigenetic changes. 
Breast cancer is the most common cancer and the principal reason of cancer death in women. In this 
context, anticancer drug is effective in reversing the epigenetic modifications. Although, trichostatin 
A (TSA) is an excellent inhibitor of histone deacetylase (HDAC) activity, it is highly toxic in nature. 
In contrast, Thymoquinone (TQ), an active component of Nigella sativa, being phytochemical is 
potentially non-toxic exhibiting anti-cancer property. The principle of this study was to examine the 
conjoint effect of TSA and TQ in inducing anticancer activity in MCF-7 breast cancer cells. Our 
experiments clearly demonstrate that TSA and TQ synergistically exert more anti-cancer effect on 
MCF-7 breast cancer cells than TSA and TQ in isolation. It is also observed that the combination of 
both TSA and TQ can more efficiently rejuvenate the expression of tumor suppressor genes (p21 and 
Maspin). Further investigation in this direction might open a new therapeutic window for the 
treatment of breast cancer.  
 
 
KEYWORDS: Breast Cancer, Trichostatin A, Thymoquinone, Anticancer drugs 
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1. INTRODUCTION 
The field of epigenetic has observed a recent breakthrough in our information concerning into 
ribonucleic acid (RNA) (Connolly et al, 2012).The Significance of epigenetic mechanisms is moving 
to the forefront of biomedical research (Vaissiere et al, 2008). Epigenetics refers to modifications in 
gene expression that are not a result of changes in the primary nucleotide sequence of a gene in 
contrary to that of genetic mutations. Instead, epigenetic alterations may result in changes in 
chromatin structure leading to a repressive chromatin state and silencing of both gene expression and 
transcription of DNA. 
1.1    CANCER 
Cancer has been considered to be brought about by a wide variety of genetic and genomic 
alterations, such as amplifications, translocations, deletions, and point mutations. It holds a dramatic 
end-point the activation of oncogenes and the inactivation of tumour-suppressor genes. However, 
cancer development is not restricted to the genetic changes, but may also involve epigenetic changes. 
Epigenetics is concerned with the inheritance of information based on gene-expression levels, as 
opposed to genetics, whose realm is that of information transmitted on the basis of gene 
sequence(Santiago Ropero et al, 2007).Breast cancer is the most common cancer and the principal 
reason of cancer death in women[WHO reports for Breast Cancer]. Early detection is essential to 
reduce cancer mortality. Analyzing the participation in an organized breast cancer screening program 
is important in order to assess the program success. Breast cancer estimation both permits minimally 
invasive breast surgery and reduce cause-specific mortality (Padoan et al, 2014). 
 The examined patterns of cervical and breast cancer screening among Asian American 
women in California and considered their screening trends over time. The pooled weighted data from 
5 cycles of the California Health Interview Survey (2001, 2003, 2005, 2007, and 2009) to examine 
breast and cervical cancer showing developments and analysts among 6 Asian nationalities. The 
calculated informative statistics, bivariate associations, multivariate logistic regressions, predictive 
margins, and 95% confidence intervals was analyzed that Multivariate analyses indicated that 
Papanicolaou test rates did not significantly change over time (77.9% in 2001 vs. 81.2% in 2007), 
but mammography receipt increased among Asian American women overall (75.6% in 2001 vs. 
81.8% in 2009). Socio-demographic and health care access factors had varied effects, with education 
and insurance coverage significantly predicting screening for certain groups. Conclusions from the 
results that  underscore the need for intervention and policy efforts that are targeted to specific Asian 
nationalities, recent immigrants, and individuals without health care access to increase screening 
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rates among Asian women in California (Chawla et al , 2014). Breast cancer is one of the common 
disorders in women. Frequency and mortality due to cancer, particularly breast cancer has been 
increasing for last 50 years, even though there is an interval in the diagnosis of breast cancer at early 
stages.  
According to World Health Organization (WHO) 2012 reports, breast cancer is the leading 
cause of death in women, accounting 23% of all cancer deaths. In Asia, one in every three women 
faces the risk of breast cancer in their lifetime as per reports of WHO 2012. Here, different breast 
cancer markers, that is, tissue markers (hormone receptors, human epidermal growth factor-2, uro 
kinase plasminogen activator, plasminogen activator inhibitor, p53 and cathepsin D), genetic markers 
(BRAC1 and 2 and gene expression microarray technique, etc.), and serum markers (CA 15.3, BR 
27.29, MCA, CA 549, carcino-embryonic antigen, onco proteins, and cytokeratins) used in present 
diagnosis, but none of the mentioned markers can diagnose breast cancer at an early stage. There is a 
disquieting need for the identification of best diagnosing marker, which can be able to diagnose even 
in early stage of breast carcinogenesis (Donepudi et al, 2014). 
1.2 CAUSES OF BREAST CANCER 
For years, scientists have been involved in sorting out the origins of human cancer, and the 
comparative roles of genetic against epigenetic abnormalities have been argued. An eruption of data 
indicating the importance of epigenetic progression, particularly those causing in the silencing of key 
regulatory genes, has directed to the awareness that genetics and Epigenetics facilitated all stages of 
cancer development (Jones et al, 2007). 
Epigenetics is defined as transferable changes in gene expression that are not accompany by 
changes in DNA sequence (Jones et al, 2007).Recent studies have exposed that Epigenetics plays a 
crucial role in cancer biology, mode of action of transportable elements, gene therapy of somatic cell 
lines, transgenic technologies, genomic imprinting, viral infections, neurological disorders, 
developmental abnormalities,  and X-chromosome inactivation. The three most important epigenetic 
signalling mechanism are: DNA methylation, histone modification and RNAi associated silencing or 
activation. 
1.3 EPIGENETICS 
Epigenetics is defined as heritable changes in gene expression that are, divergent mutations, 
not attributable to modification in the sequence of DNA. The main epigenetic mechanisms are DNA 
methylation, loss of imprinting, modifications to chromatin and non-coding RNA (Hamilton et al, 
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2011). An epigenetic feature is a steadily heritable phenotype resultant from changes in a 
chromosome without change in the DNA sequence. It involves no change in the original genetic 
program even though; non-genetic factors cause appearance of differential phenotypes in the 
organism's genes. Recent studies have exposed that epigenetics plays a vital role in cancer biology, 
mode of action of movable elements, viral infections, gene therapy of somatic cell lines, transgenic 
technologies, genomic imprinting, developmental abnormalities, neurological disorders, and X-
chromosome inactivation. The three major epigenetic signaling tools are: DNA methylation, RNAi 
associated silencing or activation and histone modification (figure: 1) 
An epigenetic alteration that silences a tumor suppressor gene — such as a gene that maintain 
the growth of the cell in check — could direct to unrestrained cellular growth. Another example 
might be an epigenetic change that "turns off" genes that help restoreing damaged DNA, primary to 
an increase in DNA damage, which in turn, increases cancer risk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Epigenetics signaling of DNA sequence 
1.3.1 DNA METHYLATION 
      DNA methylation is the covalent addition of a methyl group to the 5’-carbon (C5) position of 
cytosine bases in CpG dinucleotides. Cytosine methylation plays a significant role in a number of 
central cellular functions (Thomas et al, 2008). 
Gene silencing may arise due to methylation of DNA at the promoter region of genes. Adenine, 
guanine, cytosine and thymine are the four bases which are the building blocks of our genetic make-
up (Connolly et al, 2012).Of all epigenetic modifications, hyper methylation, have been most broadly 
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studied that causes suppression of transcription at the promoter area of tumours suppressor genes 
followed by gene silencing (Patra et al, 2008) 
1.3.2 HISTONE MODIFICATIONS 
Eukaryotic genomes are put together into a extremely dense chromatin, which imposes 
constriction on gene transcription and other chromatin-based development. To contract with this 
obstruction, histone acetylation has developed to open chromatin structure and make easy 
accessibility of transcriptional machinery to DNA templates in chromatin (figure 2). Histone 
acetylation is a reversible modification of specific residues in histone ‘‘tails’’ and is affected by 
histone acetylases (HATs) and histone deacetylases (HDACs) that normally act as transcriptional co-
activators and co-repressors, respectively (Vaissiere et al , 2008) .An wide literature documents an 
detailed collection of reversible, dynamic post-translational modifications (PTMs) namely, 
acetylation, phosphorylation, ADP-ribosylation, methylation,  ubiquitination, biotinylationm and 
SUMOylation occurring widely in the histone-tail and rarely in the core histones (Parbin et al,2014). 
 
 
 
 
 
 
 
 
 
 
                                                      Figure 2: Role of HDAC inhibitor in cancer  
1.3.3 HISTONE ACETYLATION, DEACETYLATION AND GENE REGULATION 
The Acetyl-Coenzyme A is the most important source of the acetyl group in histone 
acetylation, and the acetyl group is transferred to Co-A in deacetylation. The negatively charged 
acetyl group neutralizes the positive charge on the histone, thus, decreases the relations of the histone 
with the phosphate group of DNA. This causes the transformation of folded structure into a relaxed 
structure (euchromatin) i.e., linked with greater levels of gene transcription (Figure 3). This can be 
inverted by HDAC activity that removes acetyl tags resulting in a more condensed structure of 
closely packed DNA referred to as heterochromatin. Histone modifications have various utilities in 
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diverse biological pathways ranging from gene regulation, chromosome condensation and DNA 
repair. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Histone acetylation and deacetylation (Parbin et al, 2014) 
1.4 ANTICANCER DRUG 
Anticancer drug, also called antineoplastic drug, is recognize by any drug that is effective in 
the conduct of malignant, or cancerous, disease. There are numerous major classes of anticancer 
drugs; these comprise alkylating agents, natural products, antimetabolites, and hormones. In addition, 
there are a number of drugs that do not fall within those classes but that reveal anticancer activity and 
thus are used in the treatment of malignant disease. 
Trichostatin A (TSA), have a cytostatic and differentiating property in mammalian cell 
culture and inhibitor of histone deacetylase (HDAC) activity. The principle of this study was to 
estimate the anti-proliferative and HDAC inhibitory action of TSA in breast cancer cell lines 
(Vigushin et al ,2001) (figure 4(a)).Anticancer effects of TQ contains the inhibition of carcinogen 
metabolizing enzyme action and oxidative impairment of cellular macromolecules, reduction of 
inflammation, stimulation of cell cycle arrest and apoptosis in tumor cells, defend of tumor 
angiogenesis, and suppression of migration, invasion and metastasis of cancer cells. TQ shows 
synergistic and/or potentiating anticancer effects when combined with clinically used 
chemotherapeutic agents (Kundu et al, 2014) (figure 4 (b)). 
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Figure 4: Molecular structure of (a) Trichostatin A and (b) Thymoquinone 
1.4.1 TRICHOSTATIN A (TSA) 
Trichostatin A is a selective and potent inhibitor of histone deacetylase (HDAC). It 
selectively inhibits the removal of acetyl groups from the amino-terminal lysine residues of core 
histones, resulting in chromatin relaxation and modulation of gene expression. Trichostatin A has 
been shown to inhibit both the G1- and G2– phases of the mammalian cell cycle and has been used to 
induce apoptosis in cancer cells with low toxicity to non-cancer cells 
Histone deacetylase (HDAC) inhibitors have recently emerged as a new class of anti-cancer 
agents. Trichostatin A (TSA), a classical HDAC inhibitor, has been demonstrated to induce cell cycle 
arrest, promote cell apoptosis, and inhibit metastasis. However, the molecular mechanism underlying 
TSA function has not been fully elucidated. The histone deacetylase (HDAC) inhibitor Trichostatin 
A (TSA) is known to mediate the regulation of gene expression and anti-proliferation activity in 
cancer cells (Zohre et al , 2014). 
Hydroxamic acid an important constituent of TSA, holds antifungal activity that was 
originally isolated from Streptomyces hygroscopicus. TSA is a specific and strong HDA-inhibitor 
(HDACi) which can alter gene expression and induce apoptosis in a variety of cancer cell sat very 
low concentration (Zohre et al , 2014).In the recent investigation, it has been identified that TSA 
treated HCT cells (colon-cancer cells) induces an altered expression of cell cycle-associated genes. 
Among the 84 genes related to cell cycle control, 34 genes were significantly altered by TSA 
treatment, with 7 genes upregulated and 27 genes down regulated. Interestingly, gene expression of 
minichromosomal maintenance protein-2 (MCM-2) was significantly down regulated by TSA 
treatment. This was confirmed by quantitative RT-PCR and Western blotting. Moreover, silencing of 
MCM-2 by siRNA led to cell cycle arrest and apoptosis in HCT116 cells. In addition, TSA caused an 
increase of phosphorylated JNK, which was involved in down regulation of MCM-2. Together, our 
results suggest that MCM-2 is a novel therapeutic target of TSA in colon cancer cells. 
Trichostatin A Thymoquinone 
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Figure 5: Inhibitory Effect of Trichostatin A on HDACs 
1.4.2 THYMOQUINONE 
Nigella sativa is an annual flowering plant that is native to Mediterranean countries, India, 
and Pakistan (Gali-Muhtasib et al, 2006). The seeds of N. sativa (often mentioned as black seed or 
black cumin) are used as a spice in Eastern cooking (Burits M et al, 2000, Hajhashemi V et al, 
2004). Moreover, black seed has been used as a medicinal herb in Middle Eastern, Northern African, 
and Indian cultures for over 3000 years (Zohary D et al, 2000). Historically, the herb has been used 
to treat a number of illnesses associated with inflammation, including asthma, bronchitis, fever, 
arthritis, and rheumatism. More recently, it has been shown to have anticancer activity in animal and 
cellular models(Hasan et al, 2013).Thymoquinone (TQ) was shown to reduce tumor growth in 
several cancer models both in vitro and in vivo. So far there are only few targets of TQ including 
protein kinases have been identified. These kinases are promising candidates for targeted anticancer 
therapy, considered the complex kinase network regulated by TQ (Baba et al, 2014). Thymoquinone 
(TQ) has important roles in the prevention and treatment of cancer by controlling cell signaling 
pathways (Rahmani et al, 2014).  
The antitumor activities of TQ, a compound isolated from Nigella sativa oil, were 
investigated in breast carcinoma in vitro and in vivo. TQ induced p38 phosphorylation and ROS 
production in breast cancer cells. These inductions were found to be responsible for TQ's anti-
proliferative and pro-apoptotic effects. Moreover, TQ-induced ROS production regulated p38 
phosphorylation but not vice versa. TQ treatment was found to suppress the tumor growth and this 
effect was further enhanced by combination with doxorubicin. TQ also inhibited the protein 
expression of anti-apoptotic genes, such as XIAP, survivin, Bcl-xL and Bcl-2, in breast cancer cells 
and breast tumor xenograft. Reduced Ki67 and increased TUNEL staining were observed in TQ-
treated tumors. TQ was also found to increase the level of catalase, superoxide dismutase and 
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glutathione in mouse liver tissues. Overall, it has been demonstrated that the anti-proliferative and 
pro-apoptotic effects of TQ in breast cancer are mediated through p38 phosphorylation via ROS 
generation (Woo et al, 2012). Nigella sativa and TQ’s anti-inflammatory potential account for the 
observed analgesic, antidiabetic, and antihistaminic effects, and ability to alleviate respiratory 
diseases, rheumatoid arthritis, multiple sclerosis, and Parkinson’s disease(Salem et al, 2005). 
2. REVIEW OF LITERATURE 
cancer has been viewed as a disease that is determined by progressive genetic abnormalities, 
including mutations in oncogenes and tumour suppressor genes, and chromosomal 
abnormalities(Hanahan et al,2000 & Vogelstein  et al, 2004).There are three epigenetic effects, DNA 
methylation, histone modifications and nucleosomal remodelling, mutually interact with each other 
to regulate gene expression(Pang-Kuo Lo et al,2008).The ultimate traits of cancerous cells, i.e. 
growth signals self-sufficiency, insensitivity to growth suppressing signals, apoptosis evasion, 
unlimited replicative potential, persistent angiogenesis, tissue incursion, and metastasis cooperatively 
lead to the alteration of a typical cell to a malignant phenotype. The chronological build-up of 
aberrations that arises during carcinogenesis exhibits considerable prospects for experimental 
interferences to avert cancer initiation and treat pre-neoplastic conditions. Carcinoma of the breast, 
prostate and colon are highly prevalent maladies in the Western nations and reports for roughly half 
of the total cancer-related mortalities among men and women (Jemal A et al, 2010).Introduction 
despite a remarkable progress in developing anticancer therapies, the incidence of various cancers 
and the number of cancer-related deaths are still on the rise (Mann et al, 2005). The increasing trend 
in chemotherapy failure, recurrence of certain tumours after primary cure, and the deterioration of 
patient’s quality of life limit the real success of chemotherapy in fighting cancer (W. Baer et al, 
2006).Genetic susceptibility, environmental factors and epigenetic modifications play a key role in 
carcinogenesis. Exposure of human beings to chemical compounds in the environment is the most 
critical risk issue in malignant transformation (Oliveira et al, 2007). The chronological build-up of 
aberrations that arises during carcinogenesis exhibits considerable prospects for experimental 
interferences to avert cancer initiation and treat pre-neoplastic conditions.  
Living cells are constantly exposed to different sources of DNA damaging agents. In order to 
maintain their genomic integrity and survive, cells have evolved a complex response that either leads 
to apoptosis or cell cycle arrest. Several genes that are activated by stress responsive protein kinases 
regulate these two cellular events. In general, the genes that are activated by the stress response play 
a protective role against the cellular insults (Kimb et al, 2005). 
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2.1 EFFECT OF ANTICANCER DRUGS IN CANCER  
2.1.1 TRICHOSTATIN A 
The Histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) is known to mediate the 
control of gene expression and anti-proliferation activity in cancer cells (Zohre et al, 2014). 
According to the Xu S et al, Using cell lines representing different stages of endometrioid 
cancers the impact of DNMT inhibitor, ADC, and HDAC inhibitor, TSA, was examined on cell cycle 
and apoptosis. It was  found that while both reagents were capable of preventing cell proliferation 
and bringing cell apoptosis, it was found that TSA appeared to be a more potent apoptosis inducer, 
but with a smaller effect on cell cycle. On the other hand, ADC exhibited strong effects on cell cycle 
regulation, but had smaller impact on cell apoptosis. It was subsequently confirmed the presence of a 
strong synergism between DNMT and HDAC inhibitors. Thus, ADC and TSA exhibited strong 
cytostatic and apoptotic effects in endometrial cancer cell lines and the combined application may 
deliver the highest response (Xu S et al, 2014). 
According to the study by Sang-Min Jang et al, PUMA is a crucial regulator of apoptotic cell 
death mediated by p53-dependent and p53-independent mechanisms. In his study, it was found that 
the transcription factor Sox4 increased PUMA expression in reply to Trichostatin A (TSA), a histone 
deacetylase inhibitor in the p53-null human lung cancer cell line H1299. The protein and mRNA 
levels of PUMA were increased by TSA, resulting in apoptotic cell death (Jang et al, 2013).whereas 
according to Feng et al, PUMA was down regulated in gastric cancer cell lines and main gastric 
carcinoma tissues. Patients with low PUMA manifestation had significant decreases in complete 
survival. Ectopic PUMA appearance prevented the growth of gastric cancer cells whereas PUMA 
reduction encouraged cellular growth. It has been informed that the knockdown of limited HDAC3 
effects upregulated PUMA expression. HDAC3 could bind to PUMA promoter, which was nullified 
after TSA treatment. In compare to TSA and SB, HDAC3 siRNA failed to upregulate p53 expression 
but encouraged the interaction of p53 with PUMA promoter. In other word it may be said that, 
PUMA was down regulated in gastric cancer. HDAC3 is significant to down regulate PUMA 
expression in gastric cancer and HDAC is, like TSA, helped PUMA expression through stabilizing 
p53 in addition to HDAC3 inhibition. In combination with chemotherapy, directing HDAC3 
influence to be a capable approach to encourage apoptosis of gastric cancer cells. 
According to Ruan et al, the effect of Trichostatin A (TSA) on the gastric cancer cell line 
BGC-823 was studied for growth inhibition and apoptosis.TSA can bring apoptosis, and increase 
acetylated histone H4 in BGC-823 cells. GPNMB expression is reduced in BGC-823 cells after TSA 
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action. GPNMB is highly expressed in gastric adenocarcinoma tissue. GPNMB involved in TSA-
induced apoptosis might contribute in gastric cancer (Ruan et al, 2014). 
According to Ma et al, ESCC cells were treated with Trichostatin A (TSA) and its antitumor 
properties and related mechanisms were examined. The results showed that TSA suppressed the 
propagation of ESCCs and caused G1 phase arrest by inducing the expression of p21 and p27. TSA 
also induced cell apoptosis by improving the expression of pro‑apoptotic protein Bax and reducing 
the expression of anti‑apoptotic protein Bcl‑2. Moreover, TSA inhibited the expression of 
phosphatidylinositol‑3‑kinase (PI3K) and reduced the phosphorylation of Akt and extracellular 
signal‑regulated kinase (ERK) 1/2 in EC9706 and EC1 cell lines. High intensities of acetylated 
histone H4 were identified in TSA‑treated ESCC cell lines. Generally, it indicates that TSA 
overpowers ESCC cell growth by inhibiting the stimulation of the PI3K/Akt and ERK1/2 pathways. 
TSA also stimulates cell apoptosis complete epigenetic regulation of the appearance of 
apoptosis‑related protein (Ma et al, 2015). Whereas, according to Wang et al, the Expression of 
HDAC2 was significantly higher in ESCC than in adjacent non-tumour tissues. Additionally, the in 
vitro invasion assay found that both down regulation of HDAC2 expression and TSA treatment 
inhibited ESCC cell invasion by approximately 75%. Also, an MMP2/9-specific inhibitor sharply 
suppressed ESCC cell invasion. Furthermore, both down regulation of HDAC2 and treatment with 
TSA decreased MMP-2 and MMP-9 protein levels in ESCC cells (Wang et al, 2013). 
According to Tu et al, treatment with HDAC inhibitors Trichostatin A (TSA), but not 
suberoyl anilide hydroxamic acid (SAHA) or HDAC siRNA, can attenuate both protein and mRNA 
expressions of EGFR in lapatinib-treated triple-negative breast cancer cells, suggesting that TSA 
may suppress EGFR expression independently of HDAC inhibition. Nevertheless, TSA reduced 
EGFR 3'UTR activity and induced the gene expression of microRNA-7, a known EGFR-targeting 
microRNA. Furthermore, treatment with microRNA-7 inhibitor attenuated TSA-mediated EGFR 
suppression. These results suggest that TSA induced microRNA-7 expression to down regulate 
EGFR expression in an HDAC-independent manner (Tu et al, 2015). 
2.1.2 THYMOQUINONE 
Thymoquinone, a monoterpene present in black cumin seeds, shows pleiotropic 
pharmacological activities containing antioxidant, antidiabetic anti-inflammatory and anti-tumour 
effects. It is a compound obtained from Black Caraway seeds of Nigella Sativa and is active against 
various cancers (Syed et al, 2010). The bioactive natural yields (plant secondary metabolites) are 
extensively known to hold therapeutic importance for the inhibition and  treatment of several chronic 
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diseases containing cancer.TQ  has anti-inflammatory effects, and it inhibits tumor cell proliferation 
through modulation of apoptosis signaling, inhibition of angiogenesis, and cell cycle arrest(Banerjee 
et al, 2010).Several bioactive components of black seed have been identified, including 
thymoquinone, thymol, thymohydroquinone ,and dithymoquinone. Among them thymoquinone (TQ) 
has been reported to exhibit antioxidant, anti-inflammatory, and chemo preventive effects (Attoub et 
al, 2012). TQ inhibits investigational carcinogenesis in a wide range of animal models and has been 
shown to arrest the growth of various cancer cells in culture as well as xenograft tumours in vivo 
(Juthika et al, 2014).Two different studies have conjugated TQ with fatty acids to enhance its 
membrane penetration capacity and antitumor activity. In both studies, the antitumor activity of TQ 
was significantly improved by attaching fatty acid derived groups to the molecule (Banerjee et al, 
2010, Woo et al, 2012) 
According to Yi et al, Thymoquinone shows inhibitory properties on cell proliferation of 
many cancer cell lines and hormone-refractory prostate cancer by overpowering androgen receptor 
and E2F-1.Thymoquinone repress cell proliferation and suppress the activation of AKT and ERK. It 
blocks angiogenesis in vitro and in vivo, avoid tumour angiogenesis in a xenograft human prostate 
cancer (PC3) model in mouse and repressed human prostate tumour growth at low amount with 
almost no insignificant toxin side effects. Besides, it was detected that endothelial cells were more 
profound to thymoquinone-induced cell proliferation, cell apoptosis and migration inhibition 
associated to PC3 cancer cells. It prevents VEGF-induced ERK stimulation, but revealed no 
inhibitory effects on VEGF receptor 2 activation. Generally, results specify that thymoquinone 
prevents tumour angiogenesis and tumour development, and might be used as a possible drug 
candidate for cancer therapy. 
According to Woo CC et al, the anticancer properties of TQ on breast cancer cells, and its 
effect on the PPAR-γ beginning pathway. They establish that TQ employed strong anti-proliferative 
effect in breast cancer cells and, when joined with doxorubicin and 5-fluorouracil, enlarged 
cytotoxicity. TQ was found to increase sub-G1 growth and annexin-V positive staining, signifying 
apoptotic stimulation. Moreover, TQ activated caspases 8, 9 and 7 in a dose-dependent method. 
Migration and invasive properties of MDA-MB-231 cells were also reduced in the presence of TQ. 
Remarkably, for the first time that TQ was capable to increase PPAR-γ action and down-regulate the 
expression of the genes for Bcl-2, Bcl-xL and survivin in breast cancer cells. Moreover the rise in 
PPAR-γ activity was prevented in the presence of PPAR-γ specific inhibitor and PPAR-γ dominant 
negative plasmid, signifying that TQ may act as a ligand of PPAR-γ. Also, detected using molecular 
docking study that TQ indeed formed interactions with 7 polar residues and 6 non-polar residues 
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within the ligand-binding pocket of PPAR-γ that are described to be critical for its activity. Their 
different observations suggest that TQ may have potential effect in breast cancer prevention and 
treatment, and demonstration for that the anti-tumour effect of TQ may also be facilitated through 
variation of the PPAR-γ activation pathway (Woo et al, 2011). 
2.1.3 CURCUMIN 
Turmeric, a golden spice obtained from the rhizome of the plant Curcuma longa, has been 
used to give color and taste to food preparations since ancient times. Traditionally, this spice has 
been used in Ayurveda and folk medicine for the treatment of such ailments as gynecological 
problems, gastric problems, hepatic disorders, infectious diseases, and blood disorders. Various 
chemical constituents have been isolated from this spice, including polyphenols, sesquiterpenes, 
diterpenes, triterpenoids, sterols, and alkaloids. Curcumin, which constitutes 2-5% of turmeric, is 
perhaps the most-studied component (Gupta et al, 2012). 
According to Dahmke et al, they pyrolysis curcumin with and without coconut fat or olive oil, 
and investigated the products by high-performance liquid chromatography (HPLC). A number of 
more hydrophilic curcumin isoforms and disintegration products, including a compound later 
identified by nuclear magnetic resonance spectroscopy (NMR) as "deketene curcumin" (1,5-bis(4-
hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one), formerly described as a synthetic curcumin 
derivative, were detected. Additionally, they proved that deketene curcumin, compared to curcumin, 
exhibits higher toxicity on B78H1 melanoma cells resulting in G2 arrest. In assumption to that, 
deketene curcumin is formed as a significance of pyrolysis during common household cooking, 
showing stronger anti-cancer effects than curcumin.  
According to Goel et al, It binds to a variety of proteins and inhibits the activity of various 
kinases. Curcumin also down regulates cyclin D1, cyclin E and MDM2; and upregulates p21, p27, 
and p53. 
According to Dang et al, Paclitaxel, isolated from Taxusbrevifolia, is considered to be an 
efficacious agent against a wide spectrum of human cancers, including human cervical cancer. 
Curcumin, a nontoxic food additive, has been reported to improve paclitaxel chemotherapy in mouse 
models of cervical cancer. In this study, two human cervical cancer cell lines, CaSki and HeLa, were 
selected in which to investigate the effect of curcumin on the anticancer action of paclitaxel and 
further clarify the mechanisms. The expression levels of p53 protein and cleaved caspase-3 were 
increased significantly in the curcumin plus paclitaxel-treated HeLa and CaSki cells compared with 
those in the cells treated with paclitaxel alone (P<0.01). Significant reductions in the levels of 
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phosphorylation of IκBα and the p65-NF-κB subunit in CaSki cells treated with curcumin and 
paclitaxel were observed compared with those in cells treated with paclitaxel alone (P<0.05). This 
suggests that the combined effect of curcumin and paclitaxel was associated with the NF-κB-p53-
caspase-3 pathway. In conclusion, curcumin has the ability to improve the paclitaxel-induced 
apoptosis of HPV-positive human cervical cancer cell lines via the NF-κB-p53-caspase-3 pathway. 
Curcumin in combination with paclitaxel may provide a superior therapeutic effect on human 
cervical cancer (Dang et al, 2014). 
According to Zeighamian et al, Poly (N-isopropyl acrylamide-co-methacrylic acid) 
(PNIPAAm-MAA) is one of the hydrogel copolymers utilized in the drug delivery system for cancer 
therapy. The aim of the study was to examine the cytotoxic potential of curcumin encapsulated 
within the NIPAAm-MAA nanoparticle, on the MCF-7 breast cancer cell line. Curcumin-loaded 
NIPAAm-MAA has more cytotoxic effect on the MCF-7 cell line and efficiently inhibited the 
growth of the breast cancer cell population, compared with free curcumin. Overall, it is concluded 
that encapsulating curcumin into the NIPAAm-MAA copolymer specifies that curcumin-loaded 
NIPAAm-MAA suppresses the growth of the MCF-7 cell line could open up new possibilities for 
breast cancer treatment (Zeighamian et al, 2015). 
According to Choudhury et al, Apigenin and curcumin synergistically induced cell death and 
apoptosis and also blocked cell cycle progression at G2/M phase of A549 cells. The synergistic 
activity of apigenin and curcumin was also noticeable from their strong depolymerizing effects on 
interphase microtubules and inhibitory effect of reassembly of cold depolymerized microtubules 
when used in combinations, indicating that these ligands bind to tubulin at different sites. In silico 
modeling suggested apigenin bounds at the interphase of α-β-subunit of tubulin. Binding studies with 
purified protein also showed both apigenin and curcumin can simultaneously bind to purified tubulin. 
Understanding the mechanism of synergistic effect of apigenin and curcumin could be helped to 
develop anti-cancer combination drugs from cheap and readily available nutraceuticals. 
According to Yunos et al, Drug resistance remains an on-going challenge in ovarian cancer 
chemotherapy. The objective of this study was to determine the effect on synergism in activity from 
the sequenced combinations of cisplatin (Cis) with curcumin (Cur) and epigallocatechin-3-gallate 
(EGCG) in the human ovarian cancer cell lines. The drugs were added in binary combinations: Cis 
combined with Cur, and Cis combined with EGCG to the human ovarian A2780 and A2780 (cisR) 
cancer cell lines, using five different sequences of administration. When sequenced combinations of 
Cis with Cur and with EGCG are applied to human ovarian A2780 and A2780 (cisR) cancer cell 
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lines, lower concentrations and shorter time gap between the two additions seem to produce a higher 
cytotoxic effect (Yunos et al, 2011). 
2.1.4 SULFORAPHANE (SFN) 
TSA is a potent histone deacetylase inhibitor and can considerably enhance gene expression. 
Sulforaphane (SFN) is bioactive food component found in cruciferous vegetables and is a histone 
deacetylase inhibitor, leads to a transcriptional activation of gene expression. Sulforaphane (SFN), a 
compound found at high levels in broccoli and broccoli sprouts. 
  According to Gibbs et al, sulforaphane have the potential to reduce prostate cancer growth 
by inhibiting histone deacetylases, which are upregulated in cancer. Sulforaphane promotes HSP90 
acetylation, thereby preventing its association with AR. Moreover, AR is frequently degraded in the 
proteasome, which leads to reduce AR target gene expression and reduce AR occupancy at its target 
genes. Finally, sulforaphane inhibits HDAC6 deacetylase activity, and the effects of sulforaphane on 
AR protein are reversed by overexpression of HDAC6 and mimicked by HDAC6 siRNA. The 
inactivation by sulforaphane of HDAC6- enabled HSP90 deacetylation and subsequent decline of 
AR signaling represents a newly defined mechanism that may help explain this agent's effects in 
prostate cancer (Gibbs et al, 2009). 
 According to Nagaveni et al , the interaction of SFN, an anticancer agent, with Amyloid 
beta (Aβ)  was studied using ESI-MS. SFN is found to bind covalently and specifically with the free 
NH(2) group of N-terminal aspartic acid and the ε-amino group of lysine at positions 16 and 28. 
Aggregation assay studies showed a lesser tendency of Aβ to aggregate when SFN is present. Hence 
the present study helps in understanding the mechanism of the action of SFN on the Aβ peptide 
(Nagaveni et al, 2006). 
 According to Beaver et al, they utilized RNA sequencing and determined the 
transcriptomes of normal prostate epithelial cells, androgen-dependent prostate cancer cells, and 
androgen-independent prostate cancer cells treated with SFN. SFN treatment vigorously altered gene 
expression and resulted in distinct transcriptome profiles depending on prostate cell line. SFN also 
down-regulated the expression of genes that were up-regulated in prostate cancer cells. Network 
analysis of genes altered by SFN treatment revealed that the transcription factor Specificity protein 1 
(Sp1) was present in an average of 90.5% of networks. Sp1 protein was significantly decreased by 
SFN treatment in prostate cancer cells and Sp1 may be an important mediator of SFN-induced 
changes in expression (Beaver et al, 2014) 
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 According to Hussain et al, SFN showed cytotoxic effects on MCF-7 cells in a dose- and 
time-dependent manner by an apoptotic mode of cell death. Moreover, a combinational treatment of 
SFN and gemcitabine on MCF-7 cells resulted in growth inhibition in a synergistic manner with a 
combination index (CI) <1.  SFN was found to significantly down regulate the expression of Bcl-2, 
an anti-apoptotic gene, and COX-2, a gene involved in inflammation, in a time-dependent manner. 
These results indicate that SFN induces apoptosis and anti-inflammatory effects on MCF-7 cells via 
down regulation of Bcl-2 and COX-2 respectively. The combination of SFN and gemcitabine might 
potentiate the efficacy of gemcitabine and minimize the toxicity to normal cells. Taken together, 
SFN may be a potent anti-cancer agent for breast cancer treatment (Hussain et al, 2013). 
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3. OBJECTIVES  
1. To study cytotoxic effect of Trichostatin A (TSA) and Thymoquinone (TQ) in isolation as 
well as in conjoint treatment to breast cancer cells (MCF-7) and normal skin keratinocytes 
(HaCat).  
2. To demonstrate apoptosis inducing activity of the combination treatment in contrast to single 
agent treatment in MCF-7 breast cancer cells.  
3. To examine anti-proliferative and anti-migratory efficiency of the combination treatment in 
MCF-7 cells. 
4. To demonstrate coordinated effect of the drugs in reactivation of tumor suppressor genes 
primarily p21 and Maspin in MCF-7 breast cancer cells. 
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4. MATERIALS AND METHODS 
4.1   Cell Lines and Cell Culture: 
Human breast cancer cell line MCF7 and normal human keratinocytes HaCat were procured 
from National Centre for Cell Science (NCCS, Pune) and were cultured in Minimum Essential 
Eagle’s Medium (MEM) and Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% 
(v/v) Fetal Bovine Serum (FBS, Invitrogen) and 100 IU/mL Penicillin and 0.1 mg/mL streptomycin 
in a humified atmosphere of 5% CO2 at 37°C. The cells were harvested by trypsinization and the 
number of living cells was calculated by Trypan blue staining (0.2% v/v) using haemocytometer. 
4.2   Cell viability assay: 
This assay was done to determine the sub-lethal concentrations (IC50) of drug and 
proliferative activity of the cells in presence of drug. MCF 7 (80 % confluent) and HaCat cells were 
seeded into 96 well-plate at a density of 5×10
3
 cells/well. After 24 h, the cells were treated with 
TrichostatinA (TSA), thymoquinone (TQ) and TSA+TQ at 7 different concentrations and incubated 
for 24 h. In parallel, the cells with the solvent control (DMSO) were also treated to assess its effect 
on cells. After completion of treatment period, to detect the cell viability MTT working solution was 
prepared by diluting the stock solution (stock 5mg/ml PBS, PH 7.2) in growth medium without FBS 
to the final concentration of 0.8mg/ml. 100 μl of MTT working solution was added to each well and 
incubated for 4 h in CO2 incubator. After incubation, the media was removed without disturbing 
formazan precipitate and dissolved in 100 μl of 100% DMSO. An incubation of 15 minutes was 
carried out in dark and the colorimetric estimation of formazan product was performed at 570nm in a 
microplate reader (Perkin Elmer). The experiment was repeated thrice and the data (mean ± S.D) 
were plotted against drug concentration and non-linear regression curve fitting was performed. 
4.3    Analysis of chromatin condensation by Hoechst 33342 stain: 
For chromatin condensation assay, MCF 7 breast cancer cells (10
4
cells/well) were seeded in 
6 well culture plates and allowed to grow for one day. Then cells were treated with TSA, TQ and 
TSA + TQ as mentioned above. After 24 hours of drug treatment, cells were stained with Hoechst 
33342 (1 mg/ml) and incubated for 10 min at 37°C and images were taken under UV filter using Epi-
fluorescent Microscope (Olympus IX71) at 400 X magnification. Condensed nucleus was counted 
against total number of nucleus in the field, and the percentages of apoptotic nuclei were analyzed. 
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4.4    Measurement of DNA Damage by Comet Assay 
 
Comet assays were performed under alkaline conditions to determine the amount of double-
strand DNA breaks. Two water baths were equilibrated at 40 °C and 100 °C respectively. Then 1% 
low-gelling-temperature agarose was prepared by mixing powdered agarose with distilled water in a 
glass bottle. The bottle was placed in the 100 °C water bath for several minutes and was transferred 
into a 40°C water bath. Agarose-precoated slides were prepared by dipping the slides into molten 1% 
agarose and wiping one side clean. Agarose was allowed to air-dry to a thin film. Slides were 
prepared ahead of time and stored with desiccant. 
 
MCF-7 was subjected to treatment with TSA, TQ and TSA+TQ for 24 h. Then cells were 
harvested and added to preheated (37°C) low-melting point agarose. The solution was pipetted onto 
slides precoated with 1% agarose. The slides were allowed to lyse overnight at 4°C in alkaline lysis 
solution (1.2 M NaCl, 100 mM Na2EDTA, 0.1% sodium lauryl sarcosinate, 0.26 M NaOH, pH > 13) 
prior to immersion in alkaline electrophoresis solution (0.03 M NaOH, 2 mM Na2EDTA, pH ∼12.3). 
After 30 min, slides were placed into a horizontal electrophoresis chamber samples for 25 min (0.6 
V/cm). The slides were washed with deionized H2O to remove the alkaline buffer, stained with 
propidium iodide (10 μg/ml stock) and incubate for 20 min. The slides were then washed with water 
and examined by Epi-fluorescent Microscope (Olympus IX71). 
4.5. Clonogenic assay: 
MCF 7 cells were plated at a low density (500 cells/well) in a 6 well plate, allowed to attach 
for 24 hours prior to treating with the drugs. The cells were treated with TSA, TQ at their respective 
IC50 values and both TSA+TQ (50 nM TSA and 19 µM TQ). Cells were grown until distinct 
colonies were visible in untreated controls. Then they were fixed and stained with a mixture of 6.0% 
glutaraldehyde and 0.5% crystal violet, air dried, photographed and evaluated for colony estimation. 
4.6   Cell migration assay: 
MCF-7 were seeded to 6 well plate to create a confluent monolayer and incubated properly 
for approximately 6 hours at 37°C, allowing cells to adhere and spread on the substrate completely. 
The required number of cells for a confluent monolayer depends on both the particular cell type and 
the size of dishes and need to be adjusted appropriately. The cell monolayer was scraped in a straight 
line to create a scratch with a p200 pipette tip. 
The debris was removed and the edge of the scratch was smoothed by washing the cells once 
with 1 ml of 1XPBS, pH7.2 and then replaced with 2 ml of MEM containing TSA, TQ and TSA + 
TQ. To obtain the same field during the image acquisition markings were created to be used as 
reference points close to the scratch. The first image of the scratch was taken and referred as 0 hour. 
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After the wound in the control was healed up the photographs were taken under a phase-contrast 
microscope. 
4.7    Total Cellular RNA isolation 
The total cellular RNA was extracted using TRI reagent (Sigma), following the 
manufacturer's instructions. MCF-7 cells were homogenized using TRI reagent i.e. 1 ml of the TRI 
Reagent per 10 cm
2
 of glass culture plate surface area. After addition of the reagent, the cell lysate 
was passed several times through a pipette to form a homogenous lysate. Phase separation was done 
by allowing the samples to stand for 5 minutes at room temperature followed by addition of 0.2 ml of 
chloroform per ml of TRI reagent. Samples were covered and shaken vigorously for 15 seconds, 
allowing standing for 10 minutes at room temperature. The resulting mixture was centrifuged at 
12,000g for 15 minutes at 4°C. Centrifugation separates the mixture into 3 phases: a red organic 
phase (containing protein), an interphase (containing DNA), and a colorless upper aqueous phase 
(containing RNA). The aqueous phase was transferred into a fresh tube and 0.5 ml of isopropanol 
was added per ml of TRI Reagent & mixed. The sample was allowed to stand for 5–10 minutes at 
room temperature and centrifuged at 12,000 g for 10 minutes at 2–8 °C. The RNA precipitate formed 
a pellet on the side and bottom of the tube. The supernatant was removed and RNA pellets were 
washed by adding a minimum of 1 ml of 75% ethanol per 1 ml of TRI Reagent. The sample was 
vortexes and then centrifuged at 7,500 g for 5 minutes at 4 °C. The RNA pellets were dried briefly 
for 5–10 minutes by air drying. An appropriate volume of nuclease free water was added and mixed 
by repeated tapping at 25 °C for 10–15 minutes. 
 
4.8   Quantification of total cellular RNA 
Final preparation of RNA was analyzed using a Nano-drop UV spectrophotometric analyzer. 
The standard preparation of RNA is expected to have a 260/280 ratio of 1.8-2.0 and a 260/230 ratio 
of <1.65, which indicates the preparation to be free from proteins and oligo-peptides contamination. 
  
4.9   cDNA preparation 
In a 1.5 ml tube, 1 μg of template RNA was taken and the volume was adjusted to 11μl with 
nuclease free water. To it 1 μl of oligo-dT primer was added to make a total volume of 12 
 
μl. The tube with the contents was mixed by centrifugation and incubated at 65°C for 5 minutes. 
 
The tube was then snap cooled on ice and given a short spin. After that 4 μl of Reverse Transcriptase 
buffer (5X ) ,1 μl of Ribolock RI, 1 μl of Reverse Transcriptase, and 2 μl of 10mM dNTP mix was 
added to make a total volume of the reaction mixture 20 μl .The tube was then snap spinned for few 
minutes. The PCR was carried and the DNA was amplified under the following conditions- i.e. 42°C 
for 60 minutes and terminated at 70°C for 5 minutes. The amplified cDNA was stored at -20°C for 
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further processing. The synthesized cDNA was evaluated by performing PCR over the house keeping 
gene such as GAPDH. 
 
GAPDH mRNA expression as internal control 
The amount of cDNA of different samples was so adjusted to have the expression of 
housekeeping gene (GADPH) similar in both control and treated samples. 
 
4.10 Gradient PCR 
 
The PCR primers were chemically manufactured and procured from Sigma. A gradient PCR 
was done to optimize the annealing temperature of each set of primers. We used 3 sets of primers to 
amplify p21, Maspin and GAPDH genes having sequence as detailed in Table no.2.The annealing 
temperature for each set of primers was optimized from 50˚C to 60˚C in order to obtain the most 
suitable temperature for the primers to be annealed on the target sequence. The PCR were carried 
out using standard protocols in a thermo cycler (Bio-Rad) and the DNA was amplified under the 
following conditions: 95 °C for 5 min, 35 cycles of 95 °C for 30 s, 50˚C to 56˚C for 30 s, and 72 °C 
for 30 s, and the final extension of 72 °C for 5 min. The PCR products for each sample were 
electrophoresed on a 1.5% agarose gel to determine the optimum annealing temperature. 
Table 1: Primers used for RT-PCR Analysis 
 
 SL.  
PRIMER NAME 
 
PRIMER SEQUENCE 
 AMPLICON 
 
 
NO
. 
   
SIZE (in bp) 
 
      
 
        
 1  p21 – forward primer  5’--TGAGCCGCGACTGTGATG—3’  
 
82 
 
        
 
   P21 – reverse primer  5’--GTCTCGGTGACAAAGTCGAAGTT—3’   
 
       
 
 2  Maspin – forward primer  5’--GGAATGTCAGAGACCAAGGGA—3’  
 
139 
 
        
 
   Maspin – reverse primer  5’-- GGTCAGCATTCAATTCATCCTT—3’   
 
      
 
 3  GAPDH– forward primer  5’—GGAGCGAGATCCCTCCAAAAT—3’   
 
               197 
 
   GAPDH – reverse primer  5’—GGCTGTTGTCATACTTCTCATGG—3’   
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4.11   Gene Expression Analysis of p21, Maspin by Semi-quantitative reverse-transcription 
PCR (Semi-q-RT-PCR) 
 
MCF 7 cells were treated with sub lethal dosages of TSA, TQ& TSA +TQ for24 hours. 
Total cellular RNA was extracted from treated samples and untreated control with TriReagent 
 
(Sigma) according to the manufacturer’s instructions. CDNA was prepared using Thermo 
Scientific Revert Aid First Strand cDNA Synthesis Kit. cDNA from different treatment groups 
were used to analyze the expression of p21, Maspin and GDPH as a house keeping gene. 
 
PCR conditions: 
 
The PCR sample mixtures, in a 20 μl volume, contained 15.4μl of nuclease free water, 2 
μl of 10X PCR buffer (Thermo Scientific), 0.2 mM of dNTP (Thermo Scientific), 0.2 μM each of 
the forward and reverse primers of p21, Maspin ,GDPH  and 0.2 μlTaq DNA-polymerase 
(0.05U/μl, Pure gene) and optimized amount of each cDNA sample (in μl) was added. PCR 
amplifications of p21, Maspin and GDPH  were performed in a thermal cycler by initial 
denaturation at 95 °C for 5 min, 35 cycles of 95 °C for 30 s, 53˚C for 30 s, and 72 °C for 30 s, and 
the final extension of 72 °C for 5 min. 
4.12Agarose Gel Electrophoresis of the PCR products: 
The generated PCR products were analyzed by electrophoresis on 1.5% agarose gel. Agarose 
gel was prepared with 1X TAE (Tris Acetate EDTA, Sigma) buffer. Before casting 1.5μl of ethidium 
bromide was added to the gel. 10 μl of sample (PCR product) was loaded to each well along with 2μl 
of 5 X loading dye. 1μl of ladder was loaded. The gel was run in TAE buffer at 80 volt for 35 
minutes. 
 
4.13    Analysis of the Relative Expression level of p21 and Maspin by quantitative Reverse-
transcription PCR (q-RT-PCR) 
 
qRT-PCR  was  performed  using  SYBR®  Green  JumpStart™  Taq Ready Mix  in  the 
Realplex4 Eppendorf system for p21 and Maspin gene. The mRNA level was normalized to 
GAPDH. The primer sequences for real time PCR are same as that of semi-q-RT-PCR and are given 
in Table 1. 
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5. RESULTS AND DISCUSSION 
5.1  Determination of cytotoxic effect and IC50 value of TSA , TQ and TSA +TQ  by cell 
viability assay  
Cell viability of MCF 7 was determined after TSA , TQ and TSA+TQ treatment by MTT Assay. 
The IC50 values for the drugs were calculated. Both TSA and TQ treatment showed decrease in cell 
viability, but conjoint treatment with TSA +TQ showed higher decrease in cell viability indicating 
more cytotoxicity towards breast cancer cells. 
We determined the sub-lethal concentration of different extracts (TSA, TQ and TSA+TQ) by 
MTT assay, which was taken as standardized concentration for further treatment. The optimized IC50 
values of TSA and TQ are found to be 180 µg/ml and 34 µg/ml for 24 h MCF 7 cells (Figure 6). 
 
Figure 6.Graphical presentation of analysis of cell viability after TSA, TQ and TSA +TQ treatment 
 
5.2   Detection of apoptosis induced of TSA ,TQ  and TSA +TQ by Chromatin 
condensation assay  
The cell death inducing ability of both combination of TSA and TQ is determined by chromatin 
condensation assay. This is indicated by formation of highly condensed and fragmented apoptotic 
bodies. Here, we found that the number of condensed nuclei in TSA + TQ treatment is comparatively 
more than that of TSA and TQ treatment separately in MCF-7 breast cancer cells. The untreated 
controls show no condensed or fragmented nuclei (Figure 7). 
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Figure 7: Fluorescence microscopic images representing condensed chromatin after TSA, TQ and 
TSA + TQ treatment in MCF 7 breast cancer cells. 
 
5.3     Measurement of DNA damage induced by TSA, TQ and TSA + TQ treatment by Comet       
assay 
Comet assay denotes the extent of DNA damage due to apoptosis on application of any 
insults to the cells. The tail moment denotes the apoptosis inducing ability of extracts. The tail 
moment of comet in case of TSA+TQ treatment is higher than TSA and TQ (Figure 8). The 
characteristic comet tail length suggested the amount of DNA damaged. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Fluorescence microscopic images of comets showing DNA damage after TSA, TQ and 
TSA + TQ treatment and their histogram analysis 
 
5.4 Determination of anti-migratory activity of TSA, TQ and TSA + TQ on MCF 7 cells by 
Scratch assay  
To determine the migratory property of the MCF 7 cells after TSA, TQ and TSA +TQ 
treatment for 72 h, the scratch assay was performed. While in control, the cancer cells migrate and 
close the gap in 72 h, in treatment groups very less number of cells migrate towards the gap. 
Moreover, the wound healing ability of TSA and TQ is found to be least among all. The results 
showed that there was more migration of cells towards the scratched area in TSA + TQ treated 
cells as compared to the TSA and TQ separately treated cells in comparison with the untreated 
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plates taken as control (Figure 9). This clearly demonstrates the efficient anti-migratory property 
of TSA + TQ on breast cancer cells. 
 
 
 
 
 
 
 
 
 
 
Figure 9: Microscopic images showing changes in the migratory property of MCF 7 cells after TSA, 
TQ and TSA + TQ treatment. 
5.5 Determination of anti-proliferative activity of TSA, TQ and TSA + TQ on MCF 7 cells by 
colony formation assay   
The colony formation assay also demonstrates the anti-cancer effect of conjoint treatment with 
TSA and TQ with respect to control. The number of colonies formed is less in case of conjoint 
treatment than that of TSA and TQ in isolation (Figure 10) 
 
Figure 10: Representative images showing colony formation in MCF 7 cells after TSA, TQ and TSA 
+ TQ treatment. 
5.6 Gene Expression Analysis of p21, Maspin and GDPH  by Semi-quantitative reverse- 
transcription PCR (Semi-q-RT-PCR)   
Semi-q-RT-PCR data confirmed that the transcript level of p21 is not expressed whereas Maspin 
is slightly expressed in MCF 7 breast cancer cells. After treatment with TSA, TQ and TSA + TQ 
both p21 and Maspin expression is increased. Maspin and p21 is a tumor suppressor gene, which has 
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been reported to have low expression in breast cancer cells. Here in our study we also found the 
lower expression of Maspin and p21at transcription level, on treatment with TSA, TQ and TSA + 
TQ, the Maspin and p21is demonstrated to be up-regulated in breast cancer cells (Figure10). The 
TSA+TQ can more effectively restore the expression of p21 and Maspin than TSA and TQ. This 
denotes that TSA + TQ may have HDAC inhibitory potential. The level of GAPDH remains same in 
all cases. 
 
 
 
 
 
 
 
Figure 11: Representative images of semi-q-RT-PCR result depicting expression level of p21, 
Maspin and GDPH after TSA, TQ and TSA+TQ treatment. 
5.7  Gene Expression Analysis of p21 and Maspin by quantitative reverse transcription PCR 
(q-RT-PCR)  
The real time PCR analysis of mRNA level of Maspin and p21 shows that the p21 is up-regulated 
by five folds for TSA, three fold for TQ and four fold for TSQ with respect to control respectively 
(Figure 10). This supports our finding from semi-q-RT-PCR study. The Maspin is also demonstrated 
to be up-regulated in drug treated cancer cells. From the increase in transcript level of p21 and 
Maspin in treatment groups, it is apparent that the TSQ has HDAC inhibitory activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Representative images of q-RT-PCR result depicting expression level of p21, Maspin and 
GAPDH after TSA, TQ and TSA + TQ treatment 
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6.  CONCLUSION 
From the present investigation, it is apparent that the TSA + TQ have the anti-cancer 
potential. This is revealed from their anti-proliferative, apoptotic and anti-migratory activity. Our 
experiments clearly demonstrate that the TSA + TQ exert more anti-cancer effect on breast cancer 
cells than TSA and TQ separately. It is also observed that the TSA + TQ can more effectively restore 
the expression of p21 and Maspin with simultaneous increase in transcript level of HDAC.  
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